SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)

INTRODUCTION: Despite advances in treatment modalities, the overall prognosis of GBM remains dismal, particularly for patients with unmethylated MGMT promoter. Thus, alternative treatment strategies are warranted. Our group has previously shown that addition of Sunitinib (SU11248) to standard therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Faye, Mame Daro, Sabri, Siham, De Robles, Paula, Agnihotram, Raman, Torres-Vasquez, Alexander, Easaw, Jacob, Abdulkarim, Bassam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453790/
http://dx.doi.org/10.1093/noajnl/vdab112.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453790/
http://dx.doi.org/10.1093/noajnl/vdab112.036

Ejemplares similares